Formatech program donates fill/finish for RegeneRx's MS candidate

Formatech will donate aseptic fill and finish services for one lot of a RegeneRx Biopharmaceuticals' drug candidate to treat cardiovascular and central nervous system diseases. The donation is part of the Massachusetts contract manufacturer's Fillanthropy Program, in which the company makes a monthly fill/finish donation to a company whose product is beginning human clinical trials.

The RegeneRx Biopharmaceuticals candidate, RGN-352, is an injectable formulation of a novel therapeutic peptide known as Thymosin Beta 4, targeted at conditions best treated via systemic delivery. RegeneRx is planning early-phase trials of RGN-352 as a treatment for multiple sclerosis.

Via the Fillanthropy Program, launched last August, Formatech made a similar donation recently to Tracon for its TRC102 small-molecule inhibitor of DNA base excision repair. The program has also awarded fills to GeoVax Labs for an HIV/AIDS vaccine candidate, to KAI Pharmaceuticals for its secondary hyperparathyroidism treatment, and to ViroMed for a vaccine targeting breast cancer.

- see the announcement

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.